Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Little Impact Seen In Regulations Implementing China’s New M&A Law

This article was originally published in PharmAsia News

Executive Summary

Regulations implementing China's new law governing mergers and acquisitions set to go into effect Aug. 1 are likely to follow foreign models that review antitrust issues involved in mergers. The new rules are expected to require reviews in two areas - monopolies and national security. Any transaction that affects competition or consumer would be subject to review for anti-monopoly issues. Those that might have an impact on China's economic security would be subject to review for national-security issues. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts